Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode Raises $13.2M in Public Stock Offering

NEW YORK (GenomeWeb) – Applied BioCode announced today that it has secured $13.2 million through a public offering of its common stock.

In addition, the firm said it has also secured $8 million in total credit lines extended from an undisclosed FDIC-insured financial institution and a commercial lender.

Applied BioCode obtained US Food and Drug Administration clearance earlier this month for its MDx-3000 molecular diagnostics system along with a multiplex panel assay that tests for 17 gastrointestinal pathogens. The firm, which is a registered Cayman Islands corporation with facilities in the US and Taiwan, plans to use the new funds to commercialize the Gastrointestinal Pathogen Panel (GPP) and MDx-3000 in the US, noting in a statement that the system "will provide high-volume laboratories with an alternative to high-cost cartridge-based systems."

The GPP is the first test in a menu of multiplex infectious disease test panels that Applied BioCode will bring to market on the MDx-3000 system, the company added.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.